12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina(Moffitt Cancer Center), James J. Mulé(Moffitt Cancer Center), Jeffrey S. Weber(NYU Langone Health), Mark C. Lloyd(Moffitt Cancer Center), David Fenstermacher(University of South Florida), Michael J. Schell(Moffitt Cancer Center), Steven A. Eschrich(Moffitt Cancer Center), Vernon K. Sondak(Moffitt Cancer Center), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Anders Berglund(Moffitt Cancer Center)
Cited by 428
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k